mortality). Costs were based on 2017 Medicare reimbursement rates. Utility values were assigned from the literature. Univariate sensitivity and multivariable Monte Carlo sensitivity analyses were performed. RESULTS: At 6 years after randomization, mean costs per patient were $11,957 (AS), $17,781 (RP), and $29,238 (RT). RP and RT each resulted in a gain of 0.05 quality adjusted life years (QALYs) relative to AS (4.90 and 4.90 versus 4.85, respectively). Accordingly, the incremental cost-effectiveness ratio relative to AS was $133,314/ QALY for RP and $389,915/QALY for RT. The model was sensitive to the annual metastasis rate on AS, with a threshold of 0.7%/year, above which RP was more cost-effective than AS. On multivariable sensitivity analysis, at a willingness-to-pay (WTP) threshold of $100,000/QALY, the most cost-effective strategy was AS in 46%, RP in 44%, and RT in 10% of simulations. At a WTP threshold of $150,000/QALY, the most cost-effective strategy was RP in 44%, AS in 39%, and RT in 17% of simulations ( Figure) .
INTRODUCTION AND OBJECTIVES: Prescription drug costs represent a major source of healthcare expenditure in the United States. While medication costs are most often associated with the medical specialties, the increased use of specialty drugs for oncologic care by surgical specialists may prove to be a significant cost driver and opportunity for savings. As such, we sought to evaluate Medicare Part D Prescription Drug (MPD) utilization in order to disaggregate surgical specialty spending, evaluate cost attributed to Urologic care, and identify factors predictive of high-cost prescribing (HCP).
METHODS: Indexing by NPI number and specialty code we analyzed surgical subspecialist prescription drug cost data using the 2016 "Medicare Fee-For-Service Provider Utilization and Payment Data: Part D Prescriber Summary". Providers in the highest quartile of total prescription drug costs for this cohort were identified as HCP providers. Categorical data analysis and logistic regression were then used to identify factors associated with HCP.
RESULTS: The aggregate drug cost for all surgical specialties in 2016 was noted to be $5.96 billion dollars for over 16 million MPD beneficiaries. Urology was found to have the highest median total prescriber drug cost ($90,808.10, p<0.01) , largest median number of drug claims (1,093, p<0.01), the largest median number of MPD beneficiaries (296, p<0.01), and the likeliest to be classified as a high-cost prescriber (Odds Ratio 3.2, p<0.01) compared to all other surgical specialties. Share of spending varied regionally, with prescribers from the South most likely classified as high-cost prescribers (OR 1.4, p < 0.01). Over all, subspecialties with a greater emphasis on cancer care were more likely than general surgeons to be high-cost prescribers.
CONCLUSIONS: National spending on health care has attracted significant criticism and concern. A major cost-driver, prescription drug coverage, is increasingly attributable to surgical subspecialist care, with Urologists leading in volume and cost among MPD providers. Urologists must be aware of their significant role in driving these costs, in order to both lead in upending them and to ensure our patients' continued access to our care.
Source of Funding: none

MP29-14 HOSPITAL CHARGES FOR UROLOGIC SURGERY EPISODES OF CARE ARE RISING IN SPITE OF DECLINING COSTS
Tyler McClintock*, Cambridge, MA; Matthew Mossanen, Ye Wang, Mahek Shah, Boston, MA; Benjamin Chung, Stanford, CA; Steven Chang, Boston, MA INTRODUCTION AND OBJECTIVES: While healthcare expenditures continue to rise within the United States healthcare system, data regarding pricing trends with cost and charge evaluated separately are lacking. Analyzing these values per episode of care over time provides context on how the largely irrational pricing structure of American healthcare relates to escalating spending and how it has responded to cost containment efforts. Here, we utilize the surgical subspeciality of urology as a model for determining procedure-specific charge and cost trends in a large, population-based database.
METHODS: We selected all patients who underwent radical prostatectomy, radical nephrectomy, radical cystectomy, partial nephrectomy, extracorporeal shock wave lithotripsy (ESWL), percutaneous nephrolithotomy, ureteroscopy with lithotripsy, and transurethral resection of the prostate from 2005 to 2015 in the Premier Hospital Database. Total charges and costs, as reported by the individual hospitals, were assessed for each unique surgical encounter; median cost and charge were defined for each study year. Additionally, median charge-to-cost ratio (CCR) for each procedure was determined per year. All costs and charges were adjusted to 2016 US dollar.
RESULTS: The reported median cost per encounter for this group of procedures was $6,824 in 2005 and gradually trended downward to $5,586 in 2015 (p for trend <0.001). However, with respect to reported charge per encounter, there was a dramatic increase from $20,210 in 2005 to $25,773 in 2015 (p for trend <0.001). These general trends were observed across subgroup analyses of individual procedures.
CONCLUSIONS: These findings demonstrate a stark discordance with respect to trends in cost relative to charge per episode of urologic surgery over the preceding decade, as charges have increased steadily and substantially while hospital reported costs have declined.
This could indicate some success in cost containment for surgical episodes of care, though higher hospital charges may be increasingly employed to buttress reimbursement from third party payers and compensate for escalating costs in other areas.
Source of Funding: None
MP29-15 IMPACT OF DEPENDENT COVERAGE INSURANCE EXPANSION ON EARLY TESTICULAR CANCER DIAGNOSIS
Scott R. Hawken, Parth K. Modi, Lindsey A. Herrel, Ann Arbor, MI INTRODUCTION AND OBJECTIVES: In 2010, the Affordable Care Act (ACA) dependent coverage expansion (DCE) took effect, allowing 19-25 year olds to remain on their parent's health insurance and potentially improving access to care. Taking advantage of this natural experiment, we sought to examine whether the ACA DCE resulted in a measureable impact in testicular cancer stage at diagnosis.
METHODS: We used data from National Cancer Database to identify men diagnosed with testicular cancer aged 19-25. To evaluate the impact of DCE, we compared this group to men aged 26-34. We examined pre-and post-ACA time periods (2006-2009 vs 2011-2015, respectively) , with 2010 treated as a washout period. Our primary outcome was cancer stage at diagnosis, classified as "Early" (Stage 1) vs "Late" (Stage 2-3) . A difference-in-differences analysis was performed to isolate the impact of the DCE. A secondary outcome was insurance status and its association with cancer stage.
RESULTS: 11,175 men aged 19-25 and 19,976 aged 26-34 met study criteria. Difference-in-differences analysis revealed a significant interaction between the 19-25 age group and the post-DCE time period (OR 0.47, p[0.047, Figure) . This suggests that, relative to background trends, men eligible for DCE had lower than expected odds of late stage disease. Among those aged 19-25, rates of private insurance increased from 65.7% to 66.8%, Medicaid from 10.9% to 13.8%, and the uninsured rate decreased from 17.0% to 13.3% pre vs post-DCE (p<0.001). Among those aged 26-34, private insurance rates decreased from 73.3% to 68.5%, Medicaid increased from 8.0% to 12.6%, and the uninsured rate increased from 12.2% to 12.7% (p<0.001 for each). Overall, men on Medicaid were most likely to present with late stage disease, followed by uninsured men and those with private insurance at 46.1%, 34.5% and 26.3% respectively (P<0.001).
CONCLUSIONS: Implementation of DCE resulted in a protective effect against the increasing odds of presenting with late stage testicular cancer seen among those who were not eligible. These findings support the importance of insurance coverage in improving testis cancer outcomes. 
